Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report

Tyrosine kinase inhibitor therapy is an established standard of care for patients with NSCLC with EGFR mutations, but a worse prognosis has been observed in patients with specific EGFR exon-20 insertion mutations. Mobocertinib (TAK-788) is a novel tyrosine kinase inhibitor developed to target EGFR e...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Josette Kamel, BA, Natalie Meeder, BA, Sandra Cuellar, PharmD, BCOP, David Chan, PharmD, PhD, Michael Huber, MD, MS, Mary Pasquinelli, DNP, Alicia Hulbert, MD, Karam Khaddour, MD, Lawrence Feldman, MD
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Tyrosine kinase inhibitors Non–small cell lung cancer Exon-20 insertion Mobocertinib CNS neurotoxicity Case report Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/61551415e3464b25acbfc6de48caa7de
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:61551415e3464b25acbfc6de48caa7de
record_format	dspace
spelling	oai:doaj.org-article:61551415e3464b25acbfc6de48caa7de2021-12-02T05:03:47ZSevere Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report2666-364310.1016/j.jtocrr.2021.100241https://doaj.org/article/61551415e3464b25acbfc6de48caa7de2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2666364321001004https://doaj.org/toc/2666-3643Tyrosine kinase inhibitor therapy is an established standard of care for patients with NSCLC with EGFR mutations, but a worse prognosis has been observed in patients with specific EGFR exon-20 insertion mutations. Mobocertinib (TAK-788) is a novel tyrosine kinase inhibitor developed to target EGFR exon-20 insertion and has exhibited promising response rates and acceptable safety in phase 1 and 2 trials. We report a case of a 59-year-old woman with metastatic NSCLC and EGFR exon-20 mutation responsive to mobocertinib therapy, who developed severe depression and catatonia approximately 4 months after mobocertinib initiation, ultimately necessitating its permanent discontinuation. Given the observed severe depression in this case report, we recommend that, for patients on mobocertinib who develop neuropsychiatric adverse effects, strong consideration should be given for dose interruption or discontinuation.Josette Kamel, BANatalie Meeder, BASandra Cuellar, PharmD, BCOPDavid Chan, PharmD, PhDMichael Huber, MD, MSMary Pasquinelli, DNPAlicia Hulbert, MDKaram Khaddour, MDLawrence Feldman, MDElsevierarticleTyrosine kinase inhibitorsNon–small cell lung cancerExon-20 insertionMobocertinibCNS neurotoxicityCase reportNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENJTO Clinical and Research Reports, Vol 2, Iss 11, Pp 100241- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Tyrosine kinase inhibitors Non–small cell lung cancer Exon-20 insertion Mobocertinib CNS neurotoxicity Case report Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Tyrosine kinase inhibitors Non–small cell lung cancer Exon-20 insertion Mobocertinib CNS neurotoxicity Case report Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Josette Kamel, BA Natalie Meeder, BA Sandra Cuellar, PharmD, BCOP David Chan, PharmD, PhD Michael Huber, MD, MS Mary Pasquinelli, DNP Alicia Hulbert, MD Karam Khaddour, MD Lawrence Feldman, MD Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
description	Tyrosine kinase inhibitor therapy is an established standard of care for patients with NSCLC with EGFR mutations, but a worse prognosis has been observed in patients with specific EGFR exon-20 insertion mutations. Mobocertinib (TAK-788) is a novel tyrosine kinase inhibitor developed to target EGFR exon-20 insertion and has exhibited promising response rates and acceptable safety in phase 1 and 2 trials. We report a case of a 59-year-old woman with metastatic NSCLC and EGFR exon-20 mutation responsive to mobocertinib therapy, who developed severe depression and catatonia approximately 4 months after mobocertinib initiation, ultimately necessitating its permanent discontinuation. Given the observed severe depression in this case report, we recommend that, for patients on mobocertinib who develop neuropsychiatric adverse effects, strong consideration should be given for dose interruption or discontinuation.
format	article
author	Josette Kamel, BA Natalie Meeder, BA Sandra Cuellar, PharmD, BCOP David Chan, PharmD, PhD Michael Huber, MD, MS Mary Pasquinelli, DNP Alicia Hulbert, MD Karam Khaddour, MD Lawrence Feldman, MD
author_facet	Josette Kamel, BA Natalie Meeder, BA Sandra Cuellar, PharmD, BCOP David Chan, PharmD, PhD Michael Huber, MD, MS Mary Pasquinelli, DNP Alicia Hulbert, MD Karam Khaddour, MD Lawrence Feldman, MD
author_sort	Josette Kamel, BA
title	Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
title_short	Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
title_full	Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
title_fullStr	Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
title_full_unstemmed	Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report
title_sort	severe psychiatric symptoms in a patient with egfr exon-20 insertion mutation receiving mobocertinib: a case report
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/61551415e3464b25acbfc6de48caa7de
work_keys_str_mv	AT josettekamelba severepsychiatricsymptomsinapatientwithegfrexon20insertionmutationreceivingmobocertinibacasereport AT nataliemeederba severepsychiatricsymptomsinapatientwithegfrexon20insertionmutationreceivingmobocertinibacasereport AT sandracuellarpharmdbcop severepsychiatricsymptomsinapatientwithegfrexon20insertionmutationreceivingmobocertinibacasereport AT davidchanpharmdphd severepsychiatricsymptomsinapatientwithegfrexon20insertionmutationreceivingmobocertinibacasereport AT michaelhubermdms severepsychiatricsymptomsinapatientwithegfrexon20insertionmutationreceivingmobocertinibacasereport AT marypasquinellidnp severepsychiatricsymptomsinapatientwithegfrexon20insertionmutationreceivingmobocertinibacasereport AT aliciahulbertmd severepsychiatricsymptomsinapatientwithegfrexon20insertionmutationreceivingmobocertinibacasereport AT karamkhaddourmd severepsychiatricsymptomsinapatientwithegfrexon20insertionmutationreceivingmobocertinibacasereport AT lawrencefeldmanmd severepsychiatricsymptomsinapatientwithegfrexon20insertionmutationreceivingmobocertinibacasereport
_version_	1718400652995985408

Severe Psychiatric Symptoms in a Patient With EGFR Exon-20 Insertion Mutation Receiving Mobocertinib: A Case Report

Ejemplares similares